Company intelligence / Profile preview

Active With Me

Lund, Sweden

Ownership: Private
Development stage: Other

Overview

Active Biotech's lead programs include tasquinimod in Phase Ib/IIa for myelofibrosis and multiple myeloma, laquinimod in ongoing clinical studies for inflammatory eye disorders, and naptumomab estafenatox in Phase Ib/II for solid tumors.[1][2]

Therapeutic areas: OncologyOphthalmology
Modalities: Small moleculeAntibody-based immunotherapy
Industry: Biotech

Partnerships

NeoTX Therapeutics Ltd. (licensee for naptumomab)

Beyond the preview

Go deeper on Active With Me.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Active With Me.

Explore the full profile